Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

Summary

This is a one-site, interventional, prospective, single-arm, open-label, controlled phase-IIa trial evaluating the safety and efficacy of palbociclib in hospitalized, moderate COVID- 19 cases.

Timeline

Start

2022-04-21

Primary completion

2022-10

Completion

2022-12

Outcome

Outcome not reported

Stopped (Enrollment): “Study was withdrawn due to challenges in patient enrollment”

Drugs

Indications